This book explores the application of pharmacogenomics in tailoring diabetes treatments based on genetic profiles. It discusses how genetic factors influence the response to insulin, metformin, and other antidiabetic drugs. By integrating genetic insights, healthcare providers can optimize glycemic control and minimize side effects. Aimed at endocrinologists and geneticists, it promotes individualized approaches in diabetes care.
Julie Parker is a specialist in the role of pharmacogenomics in diabetes management, focusing on how genetic variations impact the effectiveness of diabetes medications. Her research includes studying the genetic factors that affect patients’ responses to insulin, oral hypoglycemics, and other diabetes drugs. Julie advocates for personalized diabetes treatment based on pharmacogenomic testing to improve glycemic control and minimize side effects. She educates healthcare providers on integrating pharmacogenomic insights into diabetes care for better patient management.